共 9 条
[1]
Clinical potential of COMT inhibitors as adjuvants in Parkinson’s disease. Mannisto PT. CNS Drugs . 1994
[2]
A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson’s disease. Ruottinen HM,Rinne UK. Clinical Neuropharmacology . 1996
[3]
Integrated phar-macokinetics and pharmacodynamics of the novel COMT inhibitor tolcapone during first administration to humans. Dingemanse J,Jorga KM,Schmitt M,et al. Clinical Pharmacology and Therapeutics . 1995
[4]
Tolcapone,bromocriptine, and Parkinson’s disease.French Tolcapone study Group[letter]. Agid Y,Destee A,Durig F,et al. The Lancet . 1997
[5]
Neurology[C]. The 5th International Congress of Pathophysiology,2006
[6]
Catechol-O-methyltrans-ferase inhibition with tolcapone reduces" wearing-off" phenomenon and levodopa requirements in fluctuating Parkin-sonian patients. Baas H,Beiske AG,Ghika J,et al. Journal of Neurology Neurosurgery and Psychiatry . 1997
[7]
Neurology[C]. The 5th International Congress of Pathophysiology,2006
[8]
Clinical pharmacology of COMT-in-hibitors:differences and similarities between entacapone and tolcapone. Jorga KM,Fotteler B. Acta Neurologica Scandinavica . 1996
[9]
Neurology[C]. The 5th International Congress of Pathophysiology,2006